Pacira Pharmaceuticals buy Raymond James
Start price
20.12.23
/
50%
€29.60
Target price
20.12.24
€38.31
Performance (%)
-48.99%
Price
03.10.24
€14.10
Summary
This prediction is currently active. The BUY prediction by Raymond_James for Pacira Pharmaceuticals is performing very badly with a performance of -48.99%. This prediction currently runs until 20.12.24. The prediction end date can be changed by Raymond_James at any time. Raymond_James has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 9.302% | 9.302% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by Raymond_James for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Raymond_James for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€19.10
31.07.24
31.07.24
€34.20
31.07.25
31.07.25
-20.94%
03.10.24
03.10.24